IOSR Journal Of Pharmacy And Biological Sciences (IOSR-JPBS)
e-ISSN:2278-3008, p-ISSN:2319-7676. Volume 19, Issue 5 Ser. 1 (Sept. – Oct. 2024), PP 63-65
www.Iosrjournals.Org

Empowering The Immune System, Immunotherapy In Cancer Treatment.

AUTHOR NAME : V.KARAN
QUALIFICATION : B.PHARMACY
DEPARTMENT : PHARMACOLOGY
COUNTRY : INDIAN
COLLEGE : PALLAVAN PHARMACY COLLEGE.

Background:
CANCER: A complex and devactating disease.
Cancer is a leading cause of death worldwide accounding for over 9.6 million deaths annually. Despite advancements in traditional treatment such as surgery, chemotherapy, and radiation therapy. Cancer remains a significant clinical challenge.
Limitation of traditional cancer treatments
Traditional cancer treatments often have limitations including
✓ *Systemic toxicity*
✓ *Limited efficacy*
✓ *The immune system Resistance development*
✓ *Poor quality of life*
A Powerful Ally
The immune system plays a crucial role in cancer surveillance and elimination. Immunotherapy harnesses this power to enhance anti- tumor immune response.
Immunotherapy: A Paradigm Shift
Immunotherapy has revolutionized cancer treatment by
1.Targeting specific cancer cells
2.Enhanceing immune cell function
3.Inducing ling-term remission
4.improveing quality of life

Date of Submission: 16-10-2024 Date of Acceptance: 26-10-2024

I. Introduction:

Cancer, a devastating disease affecting millions worldwide, has long been a formidable for in the medical radiation, after come with significant side effects and limited success. However, a revolutionary approach has emerged.

Immunotherapy, by harnessing the power of the immune system, immunotherapy after new hope patients and has transformed the landscape of cancer treatment.

Immunotherapy: A game- changer in cancer treatment.

Immunotherapy works by enhancing the body's natural defences to recognize and attack cancer cells.

This targeted approach has shown remarkable promise in treating various types of cancer,includingMelanoma, lung, kidney and Lymphoma.With its potential Immunotherapy has become a beacon of hope for patients and Clinicians alike,

II. Historical Milistones:

Key Milestones in Immunotherapy Development include,

✓1891: William Coley's bacterial toxins stimulate Anti-tumour immunity.
✓1990: cytokine therapy (IL-2, IFN- alpha)
✓2011: Ipilimumab (CTLA-4 inhibitor) approved for melanoma
✓2014: Pembrolizumab(PD-1 inhibitors) approved for melanoma

Image-1:



Current immunotherapy treatments works in three-district ways:

- Ramping up the immune response. The first immunotherapies, cytokines such as interferon, stimulate the growth of immune cells.
- boosting targeted therapy, the overall immune response is strengthened when Immunotherapy is combined with some targeted therapy drugs.
- releasing the brake on the immune response. Cancer cells can prodce a protein that turns off the immune response, blocking this protein releases the brake and enables the immune system to attack the cancer cell

Image-2:



Experimental work: Study design

1.Prospective,apen-label,single-arm clinical trail.
2.100 patients with advanced melanoma
3.Treatment: Pembrolizumab (200mg IV) + (Ipilimumab (3mg/kg IV)

III. Methods:

1.Patients selection: Histologocally confirmed melanoma, stage 3/4.
2.Inclusion criteria: ECOG 0-1,adequate organ function.
3.Exclusion criteria: Autoimmune disorders, prior immune theraphy.
4.Treatment duraction: 12 months or until disease progression.
5.Efficacy acessments: Tumor measurements, immune cell profiling.

IV. Results:

Efficacy:

- Objective response rate 60%.
- Progression free survival-9.5 months.
- Overall survival-18.2 months.

Immunological Response:

1.Increased CD8+T-cell infilteration in tumors ($p<0.05$)
2.Enhanced T-cell activation (CD69+) ($p<0.01$)
3.Elevated cytokine levels (IL-2) ($p<0.01$)

V. Conculsion:

Combination immunotherapy with pembrolizumab and ipilimumab demonstrated significant clinical activity and immunological responses in advanced melanoma patients.

VI. Future Disorders:

- Investigating combination regimens with other immunotherapies.
- Exploring predictive biomarkers for treatment response.
- developing personalized immunotherapy approaches.

References:

[1] Wolchok Et Al (2013) Ipilimumab Monotherapy In Patients With Pretreated Advanced Melanoma.
[2] Ribas Et Al (2015) Pembrolizumab Versus Investigator Choice Chemotherapy For Ipilimumab- Refractory Melanoma.